

# Making invariant NKT cells the new standard

Universal allogeneic cell therapies built on invariant T cells

Discover Appia

SCROLL DOWN

A powerful technology platform leveraging stem cell biology and T cell development to scale engineered NKT cell therapies

→ Our technology

Appia Bio is committed to inventing novel cellular cancer medicines with



→ Our company



## Meet our team of

pioneering biologists, immuno engineers, and cell therapy experts comprise Appia Bio's team.

→ Meet our team





Appia Bio to Present Data on API-192 at the 65th American Society for Hematology Annual Meeting and Exposition

05 Dec, 2023

Appia Bio Expands Leadership Team With Sylvaine Cases, Ph.D. Appointed Chief Business Officer and Alex Babayan, Ph.D. as Vice President, Head of Regulatory Affairs

28 Jun, 2023

Appia Bio Announces Appointment of Robert S. Negrin, M.D., to Scientific Advisory Board

15 Dec, 2022

App  
Mar  
its E  
and  
Dan  
Scie

09 Au

If you're passionate about making waves in cell therapy, we'd love to hear from you

Join our team

[Contact Us](#)



We're a biotech company founded in 2020 to discover and develop next-generation allogeneic cell therapies for cancer patients.

Meet our team

Just as the first Roman aqueduct Aqua Appia was a highly sophisticated feat of engineering built to serve more people, so too is our cellular technology platform - ACUA.

Our mission is to create novel, curative, and accessible cell therapies for patients.

Our vision is to be the leading cell therapy company transforming patients' lives through the passionate pursuit of innovation and excellence.

## Meet our team

### LEADERSHIP TEAM



**JeenJoo (JJ) Kang, PhD**  
Chief Executive Officer, Founder



**Jeff Wieszorek, MD**  
Chief Medical Officer, Founder



**Jason Damiano, PhD**  
Chief Scientific Officer



**Sylvaine Cases, PhD**  
Chief Business Officer





**Qi Wei, PhD**

Senior Vice President, Technical Operations



**David Morse**

Vice President, Quality



**Alex Babayan, PhD**

Vice President, Regulatory

**BOARD OF DIRECTORS**



**David Baltimore, PhD**

Board Chairman, Founder, President Emeritus of Caltech



**Daqing (Darren) Cai, PhD**

Managing Partner, Sherpa Healthcare Partners



**Francisco Gimenez, PhD**

Partner, 8VC



**JeenJoo (JJ) Kang, PhD**

Chief Executive Officer, Founder



**Jeff Wieszorek, MD**

Chief Medical Officer, Founder



**Lili Yang, PhD**

Associate Professor, UCLA, Founder, foundational inventor of ACUA technology



**Margo Roberts, PhD**

Former CSO of Kite Pharma and Lyell Immunopharma

**SCIENTIFIC FOUNDERS AND ADVISORY BOARD**



**David Baltimore, PhD**

Board Chairman, Founder,  
President Emeritus of Caltech



**Mitchell Kronenberg, PhD**

President and CSO, La Jolla  
institute for immunology



**Robert Negrin, MD**

Professor of medicine and former  
Chief of the Division of Blood and  
Marrow Transplantation at  
Stanford University



**Antoni Ribas, MD, PhD**

Professor of medicine, UCLA, and  
director of the tumor immunology  
program, Jonsson comprehensive  
cancer center



**Margo Roberts, PhD**

Former CSO of Kite Pharma and  
Lyell Immunopharma



**Pin Wang, PhD**

Professor at USC, Founder



**Irving Weissman, MD**

Professor and Director of the  
Institute for Stem Cell Biology and  
Regenerative Medicine, Stanford  
University




**Lili Yang, PhD**

Associate Professor, UCLA,  
Founder, foundational inventor of  
ACUA technology



## Some of our investors and partners



If you're passionate about  
making waves in cell therapy,  
we'd love to hear from you

we'd love to hear from you

Join our team

[Contact Us](#)



[Company](#)

[Technology](#)

[Pipeline](#)

[Careers](#)

[News](#)

© Appia Bio 2024 - All rights reserved · [Privacy Policy](#)

Made by ++

One powerful, patented platform – a multitude of potential therapeutic applications

SCROLL DOWN

## The unique promise of NKT cell therapies

NKT cells have unique attributes that tackle cancer heterogeneity and tumor microenvironment challenges. NKT cells are special, but also rare, which is why they've been difficult to engineer to scale. The ACUA platform provides us access to these CAR-NKT cells.


Move your cursor over this element



# Scalable, universal therapies via our proprietary ACUA Platform


## APPIA'S TECHNOLOGY

Our allogeneic off-the-shelf therapy has the potential to produce thousands of doses of CAR-NKT-cells that can be frozen and waiting for the patient at the clinic.



## CURRENT STANDARD

Autologous CAR-T therapies are individualized and produced one dose at a time through an expensive manufacturing process. This can be dependent on the health of the patient's own immune cells, which can be varied.




# The ACUA Difference: Harnessing the power of rare, potent cancer-fighting innate-like T cells

Most allogeneic cells are mature cells from donors. They are engineered, edited, and massively expanded. Massive expansion of mature cells can lead to cell exhaustion and underperformance.

Our proprietary process starts with healthy hematopoietic stem cells to drive differentiation to these subtypes of rare but potent innate-like T cells, like NKT and gamma delta T cells. As part of the ACUA differentiation process, they are engineered to be armed with chimeric antigen receptors (CARs) to target the cancer.

Once cryopreserved, these universal T cells are uniquely suited for off-the-shelf therapy for hematologic and solid cancers.



“There is tremendous potential to be explored in allogeneic cell therapies. The board and I look forward to working with this stellar team to create transformative cell therapies that will help patients and the physicians who treat them”

# A pipeline of novel therapeutic potential for cancer patients



Technology that spans the promise of both NK and T cell

If you're passionate about making waves in cell therapy, we'd love to hear from you

Join our team

[Contact Us](#)



[Company](#) [Technology](#) [Pipeline](#) [Careers](#) [News](#)

© Appia Bio 2024 - All rights reserved · [Privacy Policy](#)

Made by ++

# Make waves in cell therapy Join our team!

↓ 0 Open Positions

## Working at Appia Bio

What do pioneering biologists, immuno-engineers, and cell therapy experts have in common?

They are making the vision for Appia Bio a reality. And you could be next.

- ✓ Stay close to the science working shoulder-to-shoulder with incredible colleagues and the world's foremost experts – with open dialogue and access to our leadership team.
- ✓ Located on the westside of Los Angeles in Culver City, between the beach and downtown.



## Our values, like our technology, are super-powered and universal

### INTEGRITY

Do hard things for the right reasons.

We face challenges with courage, accountability, and candid objectivity.

### EXCELLENCE

Make groundbreaking impact.

We work with urgency on bold objectives and hold ourselves to the highest standards.

### TEAMWORK


Build strength between people.

We trust our team, collaborate respectfully, and communicate with transparency and uncompromising integrity.



Driven, passionate, thoughtful – and as killer at karaoke as you are at creating killer cells

If you're passionate about innovating the future of cancer treatment, we'd love to hear from you

 [See Open Positions](#)

Is your field of expertise not listed?

We are always looking for talented people to help us on our mission. Reach us at [our contact page](#)

If you're passionate about making waves in cell therapy, we'd love to hear from you

Contact Us



[Company](#) [Technology](#) [Pipeline](#) [Careers](#) [News](#)

© Appia Bio 2024 - All rights reserved - [Privacy Policy](#)

Made by ++

PRESS RELEASE

# Appia Bio to Present Data on API-192 at the 65th American Society for Hematology Annual Meeting and Exposition

[Read More](#)

Appia Bio Expands Leadership Team With Sylvaine Cases, Ph.D. Appointed Chief Business Officer and Alex Babayan, Ph.D. as Vice President, Head of Regulatory Affairs

Press Release - 28 Jun, 2023

Appia Bio Announces Appointment of Robert S. Negrin, M.D., to Scientific Advisory Board

Press Release - 15 Dec, 2022

Appia Bio appoints Margo Roberts, Ph.D. to its Board of Directors and names Jason Damiano, Ph.D. as Chief Scientific Officer

Press Release - 09 Aug, 2022

Appia Bio announces appointment of Irving Weissman, MD, and Mark Exley, PhD, to Scientific Advisory Board

Press Release - 02 Dec, 2021

Kite and Appia Bio announce collaboration to research and develop allogeneic cell therapies for cancer

Press Release - 05 Aug, 2021

Appia Bio names cell therapy manufacturing veteran Qi Wei, PhD as Senior Vice President of Technical Operations

Press Release - 19 May, 2021

Appia bio launches with \$52 million series a financing and establishes scientific advisory board



If you're passionate about making waves in cell therapy, we'd love to hear from you

[Join our team](#)

[Contact Us](#)

